Abstract: Coated pharmaceutical packages may comprise a glass body formed from a borosilicate glass composition having a Type 1 chemical durability according to USP 660, the glass body having an interior surface and an exterior surface and a wall extending therebetween. A low-friction thermally stable coating having a thickness of ?1 ?m may be positioned on at least a portion of the exterior surface. The low-friction coating may comprise a silane. The portion of the exterior surface of the coated pharmaceutical package may have a coefficient of friction that is at least 20% less than an uncoated pharmaceutical package formed from the same borosilicate glass composition.

Abstract: A medical component is provided which includes a first portion formed of a first elastomeric material having at least one taggant embedded or incorporated therein, and a second portion formed of a second elastomeric material. The at least one taggant has a first diffusivity relative to the first elastomeric material and a second diffusivity relative to the second elastomeric material. The second diffusivity is less than the first diffusivity.

Abstract: A transport device for medical containers includes a carrier plate which has openings for receiving medical containers, and optionally a trough-shaped container which is formed such that the carrier plate can be inserted in the trough-shaped container. The carrier plate contains a polymer and 7.5 to 50 wt.-% inorganic particles. The optional trough-shaped container contains a polymer and optionally 7.5 to 50 wt.-% inorganic particles.

Abstract: A continuous skin packaging and coating apparatus and a coating method for tablets. The continuous skin packaging and coating apparatus comprises a lower coating film unreeling roller, a waste edge reeling roller, an upper coating film unreeling roller, a lower coating heating component, an upper coating heating component, a first mold provided with a first table placing hole, a second mold provided with a second tablet placing hole, a heat-sealing plate, a cutting component, a blank tablet implanting component, and an operating mesa. The lower coating film unreeling roller and the waste edge reeling roller are provided on either side of the operating mesa. The lower coating film heating component, the blank tablet implanting component, the upper coating film unreeling roller, the upper coating film heating component, the heat-sealing plate, and the cutting component are sequentially provided above the operating mesa.

Abstract: A transparent bottle for holding a liquid includes a bottle body that includes a front wall, a rear wall and a first side wall and a second side wall that extend between the front wall and the rear wall. The first side wall includes a central portion and a front faceted portion that extends between the central portion and the front wall. The front faceted portion is curved relative to the central portion and is separated from the central portion by a front outer transition line and is separated from the front wall by a front inner transition line. A bottom that extends between the front wall, the rear wall and the first and second side walls. The bottom provides a base structure for supporting the bottle in an upright, standing position. A shoulder extends inward from the bottle body and a neck extends outward from the shoulder toward a mouth.

Abstract: A dosing cup for delivery of medicinal fluid includes a base wall, a sidewall, a first gripping portion, and a second gripping portion. The sidewall extends from the base wall to an upper rim, thereby defining a medicinal fluid-receiving volume. The first gripping portion is formed at a first position of the sidewall. The second gripping portion is formed at a second position of the sidewall opposite the first position across the medicinal fluid-receiving volume. Each of the first gripping portion and the second gripping portion include one or more anti-nesting projections that extend from an outer surface of the sidewall a distance beyond an inner diameter of the upper rim.

Abstract: A baby bottle sensor with content deduction logic is attachable to a baby bottle. The sensor uses programmed logic to deduce whether formula or some other fluid is being fed. Collected data is stored and reported to a paired Bluetooth device.

Abstract: The invention relates to an enteral adapter assembly for connecting an enteral fluid source to an enteral feed tube, the assembly comprising: an adapter including: a proximal end comprising a first connection portion for attaching to a fluid outlet provided on the enteral fluid source, and a distal end comprising a first threaded connection portion for screwing to an end of an enteral feed tube. A fluid conduit extends between the proximal and distal ends. The assembly further comprises a removable cap having a second threaded connection portion configured for screwing the cap onto the first threaded connection portion, wherein the proximal end of the adapter further comprises a locking member configured to irreversibly mate with a corresponding feature provided on the fluid outlet of the enteral fluid source as the adapter is attached to the outlet to prevent removal of the adapter from the outlet when the cap is unscrewed from the distal end of the adapter.

Abstract: Feed and flush delivery devices are described for use in switching between delivery of enteral feeding fluid and flushing/hydration fluid to a patient, with both fluids being delivered through the same closed system. The delivery devices are simpler, easier to use, and are more cost effective than known prior art valves and control devices. Independent feed and flush lines are typically received by the delivery device, which merges the two lines into a single end delivery line so that either feeding or flushing fluid, but not both at the same time, can be conveyed through the end line, as desired and selected by the user. The delivery device is loaded onto the pumping mechanism of an enteral infusion pump, and can be part of a cassette which is used in combination with a particular brand of infusion pump.

Abstract: Nutritional formulas comprising long-chain polyunsaturated fatty acids (LC-PUFAs) are provided, along with methods and devices for preparing and/or administering nutritional formulas. In some embodiments, a percentage of the LC-PUFAs in the nutritional formula are in the form of monogiycerides and/or free fatty acids. In some embodiments, the nutritional formulas do not comprise added lipase. Also provided are methods for providing nutrition to a subject, methods for improving fat absorption, methods for improving cognitive ability, methods for preventing chronic lung disease, and methods for reducing the length of time a patient requires total parenteral nutrition.

Abstract: The invention relates to an implant or medical tool made of a metal or having a surface made of a metal for use in a therapeutic treatment, wherein the implant or the tool has, on its/the surface, a coating with polycrystalline doped electrically conductive diamond, wherein the therapeutic therapy is a treatment of a microbial infection of a human or animal body, wherein the implant or the tool is connected as anode (12) in an electrochemical system in the body, wherein the electrochemical system comprises, in addition to the anode (12), a cathode (16), a power source connected in an electrically conductive manner to the anode and to the cathode, and an electrolyte comprising or consisting of a body fluid, or consists of the anode (12), a cathode (16), a power source connected in an electrically conductive manner to the anode and to the cathode, and an electrolyte comprising or consisting of a body fluid, or wherein the implant or the tool is disposed within an electrical field, by means of which a negativ

Abstract: To provide a dental glass ionomer cement composition which exhibits high mechanical properties. The dental glass ionomer cement composition of the present disclosure comprises (a) non-crosslinked polyalkenoic acid, (b) water, (c) crosslinked polyalkenoic acid: 0.01 to 10 wt. %, and (d) acid-reactive glass powder.

Abstract: A dental wrap is provided. The dental wrap includes an adhesive layer and a backing layer, which is characterized in that it does not contain an active ingredient. The present invention can improve the user's feeling of use by applying various flavors that were difficult to use in the tooth whitening agent.

Abstract: Disclosed are stable, non-irritating, skin treatment active agents containing formulations and delivery systems for topical application to the skin. The disclosed topical formulations and delivery systems provide controlled, gentle release of the active agents into the skin for the treatment of amenable skin conditions as well as for improvement of aesthetic skin properties. Also provided are methods for the formulation, manufacture and use of the disclosed formulations and delivery systems.

Abstract: The disclosure relates to a composition for dyeing keratin fibers, in particular human keratin fibers such as hair, comprising one or more dyes, one or more scleroglucan gums in a total weight content greater than or equal to 0.5% relative to the total weight of the composition, one or more mineral alkaline agents, and one or more organic alkaline agents selected from the alkanolamines. The disclosure also relates to a method for dyeing keratin fibers using said composition and to a multi-compartment device suitable for implementing said composition.

Abstract: A cosmetic composition is provided including a hemp sourced cannabidiol with malodor control combination of a marine microalgae extract and a wild indigo extract.

Abstract: The new product utilizes a novel combination of cannabidiol and niacinamide to maintain skin homeostasis through synergistic pathways which help to protect the skin of an individual.

Abstract: According to the present invention there is provided a cosmetic composition comprising a cosmetically acceptable carrier and a preservative system, wherein the preservative system comprises: (i) an antimicrobial agent; (ii) a chelating agent comprising ethylenediamine tetraacetic acid (EDTA) or a derivative thereof; and (iii) an antimicrobial booster agent selected from the group consisting of ethylhexylglycerin, caprylyl glycol, hydroxy acetophenone, caprylhydroxamic acid, phenethyl alcohol, p-anisic acid, glyceryl caprylate, levulinic acid, sodium levulinate, propanediol, hexanediol, pentylene glycol, capryloyl glycine, methylpropanediol, phenylpropanol, sodium anisate, and combinations thereof, wherein the antimicrobial agent is present in an amount of from about 0.001% to about 1% by weight of the composition.

Abstract: A cosmetic composition and method for promoting skin exfoliation are disclosed. Specifically, a cosmetic composition which includes a calcium-binding substance and a substance that changes protein structure, and thus, has an excellent exfoliation effect compared to the conventional effective raw material even at a weakly acidic-neutral pH, and has low skin irritation, and maximizes exfoliating ability through a combination of raw materials, thereby increasing efficiency and reducing side effects.

Abstract: A chewable composition for teeth-whitening comprising a first region and a second region separated by a barrier layer; the first region comprising carbamide peroxide having water content of about 2% or less, a wetting agent (e.g., glycerin), an anhydrous chewing gum base having water content of about 1% or less, an anhydrous fruit acid, and one or more gum additives; and the second region comprising a chewable composition comprising a gum base, a source of bicarbonate ion, and one or more gum additives. A kit comprising separate chewable compositions corresponding to the first and second regions, and methods for whitening teeth using the chewable composition are also provided.

Abstract: The present invention relates to topical compositions comprising D-panthenol, bis-ethylhexyloxyphenol methoxyphenyl triazine (BEMT) and hydroxyacetophenone (HAP) in specific weight ratios which show less staining.

Abstract: The subject of the present disclosure is a process for dyeing keratinous material, in particular human hair, including the following steps: Application of an agent (a) to the keratinous material, wherein the agent (a) is at least one organic silicon compound selected from silanes having one, two or three silicon atoms, said organic silicon compound including one or more hydroxyl groups and/or hydrolysable groups per molecule, and said agent (a) further including at least one oligoalkylsiloxane, and Application of an agent (b) to the keratinous material, the agent (b) including at least one colorant compound selected from the group including pigments and/or direct dyes. A second object of the present disclosure is a multi-component packaging unit which contains the two agents (a) and (b) in two separately assembled containers.

Abstract: An isolated peptide consisting of FKCRRWQWRMKKL (SEQ ID NO: 1) for preserving the natural color of the hair, or slowing the decay in the natural pigment production of the hair follicle, or reducing the appearance of hair graying is provided. Also disclosed herein are methods and compositions for preserving the natural color of the hair, or slowing the decay in the natural pigment production of the hair follicle, or reducing the appearance of hair graying in a mammal subject.

Abstract: The present invention provides hair straightening compositions comprising acrylic polymers configured to crosslink upon drying and thereby to form a film that is able to preserve hair in straightened conformation. Also provided is a hair straightening cosmetic formulation comprising said hair straightening composition and its use in straightening hair or preserving hair in a straightened conformation. The hair straightening effect is temporary and can be removed when the formulation is washed away in water or with shampoo. The cosmetic formulations of the present invention are ready to use formulations and may be applied frequently.

Abstract: The invention provides a novel oil thickener that can impart a thickening effect for oils used in cosmetics, and a novel oil-soluble copolymer that can be used as the thickener. The cosmetic oil thickener of the invention is an oil-soluble copolymer having a monomer unit composed of a hydrophilic monomer, a monomer unit composed of an easily-crystallizing hydrophobic monomer, and a monomer unit composed of a poorly-crystallizing hydrophobic monomer.

Abstract: Provided are hair treatment compositions comprising a polyurethane-urea crosslinked by at least one multi-functional chain extender, and uses thereof.

Abstract: A composition for forming a solid material at a temperature of about 60° F. to about 77° F. comprising an oil phase including one or more oils in an amount of from 30% to 70% by weight of the composition, and one or more alcohols; and an aqueous phase including one or more polyglycerides; wherein the ratio of the aqueous phase to the one or more polyglycerides does not exceed 2.5:1.

Abstract: A method of moisturizing skin of a person is disclosed. The method can include topically applying to the skin of the person a composition comprising an effective amount of an aqueous, alcoholic, or aqueous-alcoholic extract from Parkia biglobosa, wherein the composition moisturizes the skin.

Abstract: The present invention relates to a cosmetic composition for topical application to the skin comprising, in a physiologically acceptable medium, at least an effective amount of at least one aqueous extract of rose and of at least one oily extract of rose, and the use thereof in particular for promoting the natural rhythmic process of skin cells and/or improving the micro-nutritional balance of the skin.

Abstract: The present disclosure relates to a cosmetic composition, and more specifically to a cosmetic composition for skin moisturization. The composition contains, as an active ingredient, a composite seawater extract obtained by mixing each of seawater extracts of Brussels sprouts, lima beans, and artichokes. The composite extract extracted from vegetables of Brussels sprouts, lima beans and artichokes by a natural method using seawater has excellent skin water loss-preventing and skin barrier-enhancing effects, and superior skin moisturizing ability. Therefore, the cosmetic composition containing the composite extract, as an active ingredient, can be advantageously used as a cosmetic material having excellent skin moisturizing ability.

Abstract: The present invention relates in particular to a cosmetic composition for making up keratin materials, in particular the skin, the lips or the eyes, preferably the skin, comprising, in a physiologically acceptable medium, at least: a) a hydrolysate of Theobroma cacao L beans, b) a prebiotic and a probiotic, and c) one or more coloring material(s).

Abstract: Compositions, packaging systems and methods for protecting human skin and/or hair against air pollution-induced damage including Dendrobium, e.g., Dendrobium nobile are described.

Abstract: A personal care composition which exhibits excellent cleaning qualities without the use, or inclusion, of a sulfated surfactant. Generally, the personal care compositions described herein contain from about 0.01 wt % to about 0.05 wt % of aloe. The aloe vera can contain salts, which can further increase aloe vera potentiation, making the aloe vera more available to deliver consumer desired benefits such as increased hair strength as demonstrated by a decrease in hair breakage during washing. The aloe vera can contain from about 100 mg/100 g (of aloe) to about 300 mg/100 g (of aloe) of a material selected from the group consisting of sodium salt, potassium salt, calcium salt, zinc salt, magnesium salt, copper salt and mixtures thereof. Additionally, the personal care compositions described herein contain a cationic cellulose polymer. The cationic cellulose polymer can have a weight average molecular weight of from about 1 Million to about 2.2 Million, and from about 1.

Abstract: Provided is a sirtuin-1 activation agent including a natural extract, having high safety as an active ingredient, and a skin cosmetic for activating sirtuin 1. An extract of echinacea and/or banana is used as an active ingredient of the sirtuin-1 activation agent of the present invention. Further, the skin cosmetic for activating sirtuin 1 of the present invention is mixed with the extract of echinacea and/or banana.

Abstract: Materials and method for mitigating the effects of acute cannabis intoxication are provided. For example, the present disclosure describes oral formulations comprising a peppercorn, a peppercorn substitute, or an extract thereof, a pharmaceutically acceptable excipient; and optionally CBD for use alleviating one or more unpleasant side effects of acute cannabis intoxication.

Abstract: A composition is disclosed which comprises: an alphahydroxy acid selected from the group consisting of malic, lactic and glycolic acids, and combinations thereof; a water-soluble zinc salt, e.g. zinc sulphate; and, methyl salicylate, for the treatment of skin and nail disorders caused by vims and fungusin mammals, especially in humans, by topical administration of the formulation to the affected area. Also disclosed are akit comprising the formulation and an applicator, an applicator connected to a container holding the composition, and a method of treating the disorders in a subject using the formulation.

Abstract: A topical formulation comprising (a) a therapeutically effective amount of tofacitinib; (b) at least one solvent; and (c) optionally one or more other pharmaceutically acceptable excipients is provided. Also provided is a method for treating and/or preventing autoimmune diseases in a subject administering said topical formulation.

Abstract: The present invention provides a method of inhibiting an effect of a noxious insult, such as an ischaemia-reperfusion injury, to an organ of a subject, the method comprising administering zinc, or a pharmaceutically acceptable salt thereof, such as Zinc Chloride, to a subject in need thereof, wherein the zinc, or the pharmaceutically acceptable salt thereof, is administered to the subject intravascularly in an amount that is sufficient to inhibit the effect of the noxious insult.

Abstract: The present invention provides an emulsion composition comprising aprepitant for treatment of emesis. Particularly, the invention is a ready-to-use emulsion compositions comprising aprepitant and medium chain triglycerides for administration by intravenous infusion, wherein the emulsion composition is also free of ethanol. Further, the invention also provides processes of preparing such compositions and their use for the prevention and control of acute and delayed chemotherapy-induced nausea and vomiting, and/or for prevention of postoperative nausea and vomiting.

Abstract: Methods and compositions for providing long term pain relief in, for example, surgery recovery, including injecting a composition comprising a plurality of microparticles having different sizes and at least one local anesthetic loaded into the microparticles at different loading levels. Extended prolonged blockage of nerve action in sheep testing was confirmed. Some of the microparticles comprise a high loading of local anesthetic. Testing in sheep showed nerve blockage for at least six days.

Abstract: An improved medical implant device directed to, inter alia, (i) avoiding unwanted initial drug “burst” problems, (ii) providing a more level amount of drug delivery, (iii) reducing blood clotting, (iv) reducing the amount of drug material that remains in the implant device, and/or (v) novel materials for an implant device.

Abstract: Parenteral nutrition formulations for pediatric patients are disclosed. The nutritional formulations include a lipid formulation that comprises an aqueous phase and an oil phase, wherein the lipid formulation is in the form of an oil-in-water emulsion. Multi-chamber containers for parenteral nutrition administration comprising a carbohydrate formulation present in a first chamber, an amino acid formulation present in a second chamber, and the lipid formulation present in a third chamber also are disclosed.

Abstract: The present invention relates to a pharmaceutical formulation for vaginal administration, wherein the formulation comprises a pharmaceutical acceptable excipient and glucono ?-lactone, wherein the glucono ?-lactone is present in an amount of 5 to 99 wt % of the formulation. The invention also relates to a pharmaceutical formulation according to the invention for use in the prevention or treatment of a urogenital fungal infection. Furthermore, the invention relates to glucono ?-lactone (formula (III)), for use in the in the prevention or treatment of a fungal infection.

Abstract: The present invention relates to an aqueous composition comprising a macrolide immunosuppressant drug at a concentration of less than 2% w/v and an amphiphilic carbohydrate compound having a molecular weight in the range 1-50 kDa, for use in treatment of an eye disorder by topical application to the eye, wherein the amphiphilic carbohydrate compound is present at a concentration below 10% w/v of the composition. A preferred carbohydrate compound is quaternary ammonium palmitoyl glycol chitosan (GCPQ). Pharmaceutical compositions and methods of treatment are also provided. The treatment may be for instance dry eye syndromes (DES), vernal keratoconjunctivitis (VKC), eczema, atopic keratoconjunctivitis (AKC), Sjögren syndrome, post-operative refractive surgery, corneal transplant or contact lens intolerance.

Abstract: An anti-allergenic product consists of: (A) a substrate; and (B) an eyelid cleansing composition comprising: at least 0.01% w/w of a plant extract, wherein the plant extract is selected from the group consisting of Camellia sinensis leaf extract, Melaleuca alternifolia leaf oil, and mixtures thereof; and phytosphingosine hydrochloride. The substrate can be pre-moistened with the composition. The eyelid cleansing composition is configured to relieve redness, discomfort and irritation in and around the eyelid.

Abstract: Drug formulations, devices and methods are provided to deliver biologically active substances to the eye. The formulations are delivered into scleral tissues adjacent to or into the suprachoroidal space without damage to the underlying choroid. One class of formulations is provided wherein the formulation is localized in the suprachoroidal space near the region into which it is administered. Another class of formulations is provided wherein the formulation can migrate to another region of the suprachoroidal space, thus allowing an injection in the anterior region of the eye in order to treat the posterior region.

Abstract: An implant for insertion through a punctum and into a canalicular lumen of a patient. The implant includes a matrix of material, a therapeutic agent dispersed in the matrix of material, a sheath disposed over a portion of the matrix of material and configured to inhibit the therapeutic agent from being released from the matrix of material into the canalicular lumen and to allow the therapeutic agent to be released from a surface of the matrix of material to a tear film, and a retention structure configured to retain the implant within the canalicular lumen.

Abstract: The present invention relates to methods and compositions for anti-aging therapy and for the treatment and prophylaxis of age-related diseases and disorders in a human subject in need of such therapy or treatment, the methods comprising the pulmonary administration to the subject, preferably via inhalation, of composition comprising rapamycin, or a prodrug or derivative thereof.

Abstract: By the ingestion of dosage forms containing sparingly water-soluble drug particles, it is not possible to deliver drug into the blood stream at high rates, because the drug dissolution rate, and the absorption rate, are limited by solubility. Herein, therefore, dosage forms comprising a slender, three-dimensional structural framework of sparingly-soluble drug dissolved in an excipient matrix comprising at least a water-soluble polymer carrier and an amphiphilic polymer are disclosed. Upon immersion in a physiological fluid, said fluid wets the structural framework, interdiffuses with it, and the amphiphilic polymer self-assembles as micelles, thereby enhancing drug solubility. Concomitantly, the framework erodes and rapidly releases drug molecules, thus enhancing drug concentration in the fluid and the drug delivery rate into the blood stream.

Abstract: The present invention relates to a pharmaceutical aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-enyl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea, or a pharmaceutically acceptable organic or inorganic acid salt thereof, a pharmaceutically acceptable organic or inorganic acid, a pharmaceutically acceptable beta- or gamma-cyclodextrin and water, that is a clear solution, with the proviso that the organic or inorganic acid (including a salt thereof) is not a sulphonic acid. Such a formulation is particularly suitable for intravenous or parenteral administration to a patient.